<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927315</url>
  </required_header>
  <id_info>
    <org_study_id>2871P</org_study_id>
    <nct_id>NCT01927315</nct_id>
  </id_info>
  <brief_title>Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes</brief_title>
  <official_title>Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-standing diabetes is often complicated by retinopathy. The mechanisms that induce the
      development of diabetic retinopathy are incompletely understood and include alterations in
      bone marrow derived vasculogenic cells called &quot;endothelial progenitor cells&quot;.

      Fenofibrate is a PPAR-alpha agonist used for the treatment of mixed dislipidemia and
      hypertriglyceridemia. In a trial conducted in type 2 diabetic patients, the drug fenofibrate
      has reduced retinopathy-related endpoints suggesting a direct effect of the drug on the
      mechanisms that drive the development of this complication.

      Herein, the investigators hypothesize that fenofibrate treatment can increase circulating EPC
      levels in diabetic patients with retinopathy, compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-standing diabetes is often complicated by retinopathy. The mechanisms that induce the
      development of diabetic retinopathy are incompletely understood and include alterations in
      bone marrow derived vasculogenic cells called &quot;endothelial progenitor cells&quot;.

      Fenofibrate is a PPAR-alpha agonist used for the treatment of mixed dislipidemia and
      hypertriglyceridemia. In addition to lowering triglyceride-rich lipoproteins, PPAR-alpha
      agonism with fenofibrate has several additional molecular benefit on the vessel wall, such as
      reduction of inflammation. In a trial conducted in type 2 diabetic patients, the drug
      fenofibrate has reduced retinopathy-related endpoints suggesting a direct effect of the drug
      on the mechanisms that drive the development of this complication.

      Preliminary data of ours on the effects of fenofibrate on cultured EPC show that this drug
      has the potential to improve EPC and, consequently, may benefit patients with retinopathy.

      Herein, the investigators hypothesize that fenofibrate treatment can increase circulating EPC
      levels in diabetic patients with retinopathy, compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial progenitor cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in endothelial progenitor cell (EPC) levels in fenofibrate-treated vs placebo-treated patients over 12 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating progenitor cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in circulating progenitor cell (CPC) levels in fenofibrate-treated vs placebo-treated patients over 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in Triglycerideslevels in fenofibrate-treated vs placebo-treated patients over 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablets daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 145 mg</intervention_name>
    <description>Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.</description>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>Fulcrosupra 145 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Placebo tablets once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or type 2 diabetes

          -  Diabetic retinopathy

          -  Age 18-70

          -  Both sexes

        Exclusion Criteria:

          -  Age &lt;18 or &gt;70 at enrollment

          -  Hereditary muscle disorders

          -  Uncontrolled hypothyroidism

          -  Elevated alcohol consumption

          -  Renal failure

          -  Hepatic failure

          -  Allergy to fenofibrate or excipients

          -  Acute / chronic pancreatitis

          -  Pregnancy and lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Paolo Fadini, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Padova, Diabetes Outpatient Clinic</name>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2013</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cells</keyword>
  <keyword>Regeneration</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

